Questions aim low, answers land high: the dialogue keeps correcting expectations upward with facts already in hand
The model's full reasoning — Q3 2016 call → NOThe question asks whether there is a recurring mismatch in level between what questioners assume and what management reports, with the mismatch running upward. I need to analyze the Q&A portion of the transcript. Let me look at the Q&A exchanges: 1. First question from Do Kim (BMO): Asks about whether the randomized Phase 2 data will be the basis for filing, and whether they expect to run another trial. Management says they believe the study has potential to support accelerated registration. Then asks about FDA feedback on the protocol revision - management says they haven't discussed with FDA but the study design is typically supportive. Then asks about increasing target enrollment - management says they are continuing to ramp sites. Then asks about the bar for NK cell drug in AML - management says they expect response rates in the 30-50% range based on prior experience, and will look at biomarkers. 2. Second question from unidentified (Wells Fargo): Asks about sham treatment for control, and about whether they need to add CMV patients to meet statistical criteria. Management explains stratification and maintaining minimum CMV positive patients. Then asks about moving into mismatched setting - management says they will think about it, mentions haploidentical transplantation as an area of interest. Then asks about NK cell manufacturing and checkpoint resistance durability - management says first clinical experience will be single donor/single patient, and they will explore multiple doses. 3. Third question from Mark Breidenbach (Roth Capital): Asks about whether blinding is really necessary for GvHD assessment given it's fairly objective. Management explains there are subjective components (skin involvement, diarrhea reporting). Then asks about timing of Phase 1 data - management says they will report as they clear safety hurdle. Then asks about Juno collaboration and whether they're getting closer to first target - management says they don't have visibility into Juno's decision-making but have delivered data packages. 4. Fourth question from Ren Benjamin (Raymond James): Asks about what would constitute statistically significant benefit - management explains p value less than 0.05 and gives example of reducing GvHD from 50% to 20%. Then asks about enrollment timing - management says they were screening while amendment was processing but didn't enroll.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| EGP | EastGroup Properties, Inc. | Q4 2023 | 2024-02-08 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| ADM | Archer-Daniels-Midland Company | Q4 2022 | 2023-01-26 | C+ |
| HBAN | Huntington Bancshares Incorporated | Q4 2022 | 2023-01-20 | B |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| ICL | ICL Group Ltd | Q3 2022 | 2022-11-09 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| HLNE | Hamilton Lane Incorporated | Q1 2023 | 2022-08-02 | C+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| PRGS | Progress Software Corporation | Q2 2022 | 2022-06-28 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| BHF | Brighthouse Financial, Inc. | Q1 2022 | 2022-05-10 | C |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| STM | STMicroelectronics NV | Q3 2018 | 2018-10-24 | C+ |
| TMHC | Taylor Morrison Home Corporation | Q2 2018 | 2018-08-01 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| LAUR | Laureate Education, Inc. | Q1 2018 | 2018-05-13 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| KRG | Kite Realty Group Trust | Q1 2018 | 2018-04-26 | C+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| SNA | Snap-on Incorporated | Q3 2017 | 2017-10-19 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DHR | Danaher Corporation | Q1 2017 | 2017-04-20 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| JHX | James Hardie Industries plc | Q3 2016 | 2016-02-19 | B+ |
GOGO · Q1 2016 → YESThe question is about whether there's a clear, recurring mismatch where analysts assume a more modest/cautious/troubled version, and management corrects UPWARD with things already happening. YES The analysts' questions repeatedly frame the business around cautious or risk-oriented assumptions—such as ARPA trajectory concerns amid competition, cash and liquidity needs, potential sentiment issues with the Gogo brand, and competitive pressures from Panasonic—while management consistently corrects upward by citing concrete, already-realized facts: record revenues, 2Ku now in service on AeroMexico and IAG, over 1,000 planes awarded, Delta increases, install records, and backlog progress already achieved. This pattern repeats across multiple exchanges, with management pointing to present-tense operational realities that exceed the cautious premises embedded in the questions.
LAUR · Q1 2018 → YESThe question is about whether there's a clear, recurring mismatch in level between what the questioners assume and what management reports, with the mismatch running UPWARD. Analysts think more modest...YES The transcript shows a clear recurring mismatch running upward. Analysts repeatedly probe cautious angles—Chile as a potential end rather than final ruling, Brazil FIES exposure as a risk, margin phasing and guidance including divestitures, Turkey as needing update, FCF not raised despite Chile, leverage post-St. Augustine, and Accelerator 2.0 health sciences—framing the business around lingering uncertainties or modest upside.
JHX · Q3 2016 → YESThe question is about whether there's a clear, recurring mismatch where analysts assume a more modest/cautious/troubled version, and management corrects UPWARD with concrete things already happening. ...NO The transcript shows analysts probing for signs of weakness or slowdowns (seasonal margins, destocking, Europe performance, PDG pickup, volumes vs targets), but management repeatedly corrects upward with concrete current facts: strong Q3 margins (2.6 points better), no destocking, plants running well, costs controlled, 12% volume growth, Europe already through the one-off, and inventory normalized.